Parameters | Univariate analysis | Multivariate analysisc |
---|
HRb (95% CI) |
p
| HRb (95% CI) |
p
|
---|
Variation (D8-D1) |
Human FGF (pg/mL) | 1.24 | (1.10–1.39) | < 0.001 | 1.16 | (1.03–1.31) | 0.016 |
PlGF (pg/mL) | 1.01 | (0.98–1.04) | 0.51 | – | | |
SCF sR/c-kit (ng/mL) | 1.04 | (0.74–1.45) | 0.83 | – | | |
sE-Selectin (ng/mL) | 0.99 | (0.96–1.01) | 0.46 | – | | |
TSP-1 (μg/mL) | 1.00 | (0.99–1.01) | 0.98 | – | | |
VEGF (ng/mL) | 1.30 | (0.30–5.65) | 0.73 | – | | |
VEGF-C (ng/mL) | 1.08 | (0.83–1.42) | 0.57 | – | | |
- aConsidering the absence of difference statistically significant, the data from the two arms were pooled
- bFor each biomarker, HR represents the hazard ratio for an increase of one unit, as estimated including the baseline value
- cFactors associated with PFS with p < 0.20 in univariate analysis were included in a stepwise multivariate model: tumor location, medical history, PIGF on D1, VEGF-C on D1 and variation (D8-D1) of human FGF. Only medical history, VEGF-C on D1 and human FGF variation (D8-D1) were significantly associated with PFS in multivariate analysis. The HR for variation (D8-D1) of human FGF adjusted by medical history and VEGF-C by D1 is presented in the table. The adjusted HRs for medical history and biomarker on D1 were de novo = 2.39 (95% CI: 1.09–5.26), p = 0.030, and VEGF-C = 0.73 (0.57–0.94), p = 0.015, respectively. Other parameters were associated with PFS with a p-value > 0.05 and were removed from the model: tumor location (HR = 1.33 (95% CI: 0.61–2.90), p = 0.47) and PIGF pg/mL on D1 (HR = 1.00 (95%CI: 0.98–1.03), p = 0.70)